Brief: Kymera Therapeutics Announces First Participant Dosed In Phase 1 Trial Of Oral Irak4 Degrader, KT-485, And Milestone Achievement Under Sanofi Collaboration
09/06/2026 12:02
BRIEF-Kymera Therapeutics Announces First Participant Dosed In Phase 1 Trial Of Oral Irak4 Degrader, KT-485, And Milestone Achievement Under Sanofi Collaboration June 9 (Reuters) - Kymera Therapeutics Inc KYMR.O:
KYMERA THERAPEUTICS ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1 TRIAL OF ORAL IRAK4 DEGRADER, KT-485, AND MILESTONE ACHIEVEMENT UNDER SANOFI COLLABORATION
KYMERA THERAPEUTICS - RECEIVE S $20 MILLION MILESTONE PAYMENT FROM SANOFI
KYMERA THERAPEUTICS - ELIGIBLE FOR UP TO $975 MILLION IN KT-485 MILESTONES
Source text: ID:nGNX90KX36
Further company coverage: KYMR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer